Aldeyra Therapeutics (ALDX) Competitors

$1.68 -0.03 (-1.47%)

As of 02:14 PM Eastern

ALDX vs. PBYI, XFOR, AKBA, OVID, and IRD

Should you buy Aldeyra Therapeutics stock or one of its competitors? MarketBeat compares Aldeyra Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Aldeyra Therapeutics include Puma Biotechnology (PBYI), X4 Pharmaceuticals (XFOR), Akebia Therapeutics (AKBA), Ovid Therapeutics (OVID), and Opus Genetics (IRD). These companies are all part of the "pharmaceutical products" industry.

How does Aldeyra Therapeutics compare to Puma Biotechnology?

Puma Biotechnology (NASDAQ:PBYI) and Aldeyra Therapeutics (NASDAQ:ALDX) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, earnings, institutional ownership, profitability, dividends, risk, analyst recommendations and media sentiment.

Aldeyra Therapeutics has a consensus price target of $5.50, suggesting a potential upside of 228.36%. Given Aldeyra Therapeutics' higher possible upside, analysts clearly believe Aldeyra Therapeutics is more favorable than Puma Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Puma Biotechnology	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Aldeyra Therapeutics	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Aldeyra Therapeutics had 17 more articles in the media than Puma Biotechnology. MarketBeat recorded 27 mentions for Aldeyra Therapeutics and 10 mentions for Puma Biotechnology. Puma Biotechnology's average media sentiment score of 0.57 beat Aldeyra Therapeutics' score of 0.19 indicating that Puma Biotechnology is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Puma Biotechnology	0 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Aldeyra Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	15 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Puma Biotechnology has higher revenue and earnings than Aldeyra Therapeutics. Aldeyra Therapeutics is trading at a lower price-to-earnings ratio than Puma Biotechnology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Puma Biotechnology	$227.18M	1.62	$31.11M	$0.48	15.07
Aldeyra Therapeutics	N/A	N/A	-$33.85M	-$0.46	N/A

Puma Biotechnology has a beta of 1.24, meaning that its stock price is 24% more volatile than the broader market. Comparatively, Aldeyra Therapeutics has a beta of 1.16, meaning that its stock price is 16% more volatile than the broader market.

Puma Biotechnology has a net margin of 10.69% compared to Aldeyra Therapeutics' net margin of 0.00%. Puma Biotechnology's return on equity of 20.30% beat Aldeyra Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Puma Biotechnology	10.69%	20.30%	12.05%
Aldeyra Therapeutics	N/A	-57.34%	-36.33%

61.3% of Puma Biotechnology shares are held by institutional investors. Comparatively, 59.7% of Aldeyra Therapeutics shares are held by institutional investors. 22.2% of Puma Biotechnology shares are held by insiders. Comparatively, 9.6% of Aldeyra Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Puma Biotechnology beats Aldeyra Therapeutics on 11 of the 14 factors compared between the two stocks.

How does Aldeyra Therapeutics compare to X4 Pharmaceuticals?

Aldeyra Therapeutics (NASDAQ:ALDX) and X4 Pharmaceuticals (NASDAQ:XFOR) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, media sentiment, risk, earnings, profitability, analyst recommendations and valuation.

Aldeyra Therapeutics presently has a consensus price target of $5.50, suggesting a potential upside of 228.36%. X4 Pharmaceuticals has a consensus price target of $8.50, suggesting a potential upside of 111.44%. Given Aldeyra Therapeutics' higher probable upside, equities analysts clearly believe Aldeyra Therapeutics is more favorable than X4 Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aldeyra Therapeutics	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
X4 Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

In the previous week, Aldeyra Therapeutics had 15 more articles in the media than X4 Pharmaceuticals. MarketBeat recorded 27 mentions for Aldeyra Therapeutics and 12 mentions for X4 Pharmaceuticals. X4 Pharmaceuticals' average media sentiment score of 1.11 beat Aldeyra Therapeutics' score of 0.19 indicating that X4 Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aldeyra Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	15 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
X4 Pharmaceuticals	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Aldeyra Therapeutics has higher earnings, but lower revenue than X4 Pharmaceuticals. Aldeyra Therapeutics is trading at a lower price-to-earnings ratio than X4 Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aldeyra Therapeutics	N/A	N/A	-$33.85M	-$0.46	N/A
X4 Pharmaceuticals	$9.01M	42.06	-$79.20M	-$4.54	N/A

Aldeyra Therapeutics has a beta of 1.16, meaning that its share price is 16% more volatile than the broader market. Comparatively, X4 Pharmaceuticals has a beta of 0.31, meaning that its share price is 69% less volatile than the broader market.

Aldeyra Therapeutics has a net margin of 0.00% compared to X4 Pharmaceuticals' net margin of -1,106.30%. Aldeyra Therapeutics' return on equity of -57.34% beat X4 Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aldeyra Therapeutics	N/A	-57.34%	-36.33%
X4 Pharmaceuticals	-1,106.30%	-94.90%	-48.09%

59.7% of Aldeyra Therapeutics shares are owned by institutional investors. Comparatively, 72.0% of X4 Pharmaceuticals shares are owned by institutional investors. 9.6% of Aldeyra Therapeutics shares are owned by company insiders. Comparatively, 1.1% of X4 Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Aldeyra Therapeutics beats X4 Pharmaceuticals on 9 of the 15 factors compared between the two stocks.

How does Aldeyra Therapeutics compare to Akebia Therapeutics?

Aldeyra Therapeutics (NASDAQ:ALDX) and Akebia Therapeutics (NASDAQ:AKBA) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their institutional ownership, media sentiment, dividends, valuation, risk, profitability, earnings and analyst recommendations.

Aldeyra Therapeutics has a net margin of 0.00% compared to Akebia Therapeutics' net margin of -8.83%. Aldeyra Therapeutics' return on equity of -57.34% beat Akebia Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aldeyra Therapeutics	N/A	-57.34%	-36.33%
Akebia Therapeutics	-8.83%	-62.72%	-5.66%

In the previous week, Aldeyra Therapeutics had 6 more articles in the media than Akebia Therapeutics. MarketBeat recorded 27 mentions for Aldeyra Therapeutics and 21 mentions for Akebia Therapeutics. Aldeyra Therapeutics' average media sentiment score of 0.19 beat Akebia Therapeutics' score of -0.43 indicating that Aldeyra Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aldeyra Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	15 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Akebia Therapeutics	1 Very Positive mention(s)	3 Positive mention(s)	3 Neutral mention(s)	3 Negative mention(s)	1 Very Negative mention(s)	Neutral

59.7% of Aldeyra Therapeutics shares are owned by institutional investors. Comparatively, 33.9% of Akebia Therapeutics shares are owned by institutional investors. 9.6% of Aldeyra Therapeutics shares are owned by company insiders. Comparatively, 4.3% of Akebia Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Aldeyra Therapeutics presently has a consensus price target of $5.50, suggesting a potential upside of 228.36%. Akebia Therapeutics has a consensus price target of $4.67, suggesting a potential upside of 300.57%. Given Akebia Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Akebia Therapeutics is more favorable than Aldeyra Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aldeyra Therapeutics	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Akebia Therapeutics	2 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.20

Aldeyra Therapeutics has a beta of 1.16, meaning that its stock price is 16% more volatile than the broader market. Comparatively, Akebia Therapeutics has a beta of 0.35, meaning that its stock price is 65% less volatile than the broader market.

Akebia Therapeutics has higher revenue and earnings than Aldeyra Therapeutics. Akebia Therapeutics is trading at a lower price-to-earnings ratio than Aldeyra Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aldeyra Therapeutics	N/A	N/A	-$33.85M	-$0.46	N/A
Akebia Therapeutics	$232.40M	1.34	-$5.34M	-$0.08	N/A

Summary

Aldeyra Therapeutics beats Akebia Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Aldeyra Therapeutics compare to Ovid Therapeutics?

Aldeyra Therapeutics (NASDAQ:ALDX) and Ovid Therapeutics (NASDAQ:OVID) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their institutional ownership, media sentiment, risk, dividends, profitability, analyst recommendations, earnings and valuation.

Aldeyra Therapeutics has a net margin of 0.00% compared to Ovid Therapeutics' net margin of -240.11%. Ovid Therapeutics' return on equity of -31.36% beat Aldeyra Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aldeyra Therapeutics	N/A	-57.34%	-36.33%
Ovid Therapeutics	-240.11%	-31.36%	-24.81%

In the previous week, Aldeyra Therapeutics had 22 more articles in the media than Ovid Therapeutics. MarketBeat recorded 27 mentions for Aldeyra Therapeutics and 5 mentions for Ovid Therapeutics. Ovid Therapeutics' average media sentiment score of 1.10 beat Aldeyra Therapeutics' score of 0.19 indicating that Ovid Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aldeyra Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	15 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Ovid Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Ovid Therapeutics has higher revenue and earnings than Aldeyra Therapeutics. Ovid Therapeutics is trading at a lower price-to-earnings ratio than Aldeyra Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aldeyra Therapeutics	N/A	N/A	-$33.85M	-$0.46	N/A
Ovid Therapeutics	$7.12M	51.77	-$17.41M	-$0.29	N/A

Aldeyra Therapeutics presently has a consensus price target of $5.50, suggesting a potential upside of 228.36%. Ovid Therapeutics has a consensus price target of $5.13, suggesting a potential upside of 83.30%. Given Aldeyra Therapeutics' higher possible upside, analysts plainly believe Aldeyra Therapeutics is more favorable than Ovid Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aldeyra Therapeutics	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Ovid Therapeutics	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.89

Aldeyra Therapeutics has a beta of 1.16, meaning that its share price is 16% more volatile than the broader market. Comparatively, Ovid Therapeutics has a beta of 0.18, meaning that its share price is 82% less volatile than the broader market.

59.7% of Aldeyra Therapeutics shares are owned by institutional investors. Comparatively, 72.2% of Ovid Therapeutics shares are owned by institutional investors. 9.6% of Aldeyra Therapeutics shares are owned by company insiders. Comparatively, 13.1% of Ovid Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Ovid Therapeutics beats Aldeyra Therapeutics on 11 of the 16 factors compared between the two stocks.

How does Aldeyra Therapeutics compare to Opus Genetics?

Opus Genetics (NASDAQ:IRD) and Aldeyra Therapeutics (NASDAQ:ALDX) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, risk, earnings, dividends, media sentiment, analyst recommendations, institutional ownership and profitability.

In the previous week, Aldeyra Therapeutics had 10 more articles in the media than Opus Genetics. MarketBeat recorded 27 mentions for Aldeyra Therapeutics and 17 mentions for Opus Genetics. Aldeyra Therapeutics' average media sentiment score of 0.19 beat Opus Genetics' score of -0.47 indicating that Aldeyra Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Opus Genetics	0 Very Positive mention(s)	1 Positive mention(s)	6 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
Aldeyra Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	15 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Aldeyra Therapeutics has a net margin of 0.00% compared to Opus Genetics' net margin of -892.36%. Aldeyra Therapeutics' return on equity of -57.34% beat Opus Genetics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Opus Genetics	-892.36%	-709.20%	-220.01%
Aldeyra Therapeutics	N/A	-57.34%	-36.33%

15.0% of Opus Genetics shares are held by institutional investors. Comparatively, 59.7% of Aldeyra Therapeutics shares are held by institutional investors. 11.7% of Opus Genetics shares are held by company insiders. Comparatively, 9.6% of Aldeyra Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Aldeyra Therapeutics has lower revenue, but higher earnings than Opus Genetics. Opus Genetics is trading at a lower price-to-earnings ratio than Aldeyra Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Opus Genetics	$11.98M	29.97	-$49.59M	-$1.33	N/A
Aldeyra Therapeutics	N/A	N/A	-$33.85M	-$0.46	N/A

Opus Genetics has a beta of 0.62, meaning that its share price is 38% less volatile than the broader market. Comparatively, Aldeyra Therapeutics has a beta of 1.16, meaning that its share price is 16% more volatile than the broader market.

Opus Genetics currently has a consensus price target of $10.20, indicating a potential upside of 102.78%. Aldeyra Therapeutics has a consensus price target of $5.50, indicating a potential upside of 228.36%. Given Aldeyra Therapeutics' higher probable upside, analysts plainly believe Aldeyra Therapeutics is more favorable than Opus Genetics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Opus Genetics	2 Sell rating(s)	0 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.79
Aldeyra Therapeutics	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Aldeyra Therapeutics beats Opus Genetics on 11 of the 16 factors compared between the two stocks.

Get Aldeyra Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ALDX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ALDX vs. The Competition

Export

Metric	Aldeyra Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$100.43M	$3.05B	$6.29B	$12.48B
Dividend Yield	N/A	1.96%	2.79%	5.30%
P/E Ratio	-3.62	18.91	20.91	25.60
Price / Sales	N/A	281.93	548.78	75.41
Price / Cash	N/A	56.53	42.94	55.34
Price / Book	2.39	4.36	9.87	6.72
Net Income	-$33.85M	$72.19M	$3.55B	$333.73M
7 Day Performance	-3.18%	-0.91%	-0.24%	0.38%
1 Month Performance	-6.42%	0.03%	1.44%	4.02%
1 Year Performance	-22.81%	46.00%	41.01%	36.37%

Aldeyra Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ALDX Aldeyra Therapeutics	2.8736 of 5 stars	$1.68 -1.5%	$5.50 +228.4%	-18.3%	$100.43M	N/A	N/A	10	Trending News Earnings Report Analyst Revision
PBYI Puma Biotechnology	1.4538 of 5 stars	$7.53 +0.5%	N/A	+138.2%	$381.18M	$228.37M	12.34	200	Positive News
XFOR X4 Pharmaceuticals	3.0493 of 5 stars	$4.21 +0.5%	$8.50 +101.9%	+27.8%	$380.95M	$35.11M	N/A	80	Positive News Analyst Revision
AKBA Akebia Therapeutics	2.2124 of 5 stars	$1.50 +7.1%	$4.67 +211.1%	-52.4%	$375.55M	$236.20M	N/A	430	Earnings Report Analyst Revision
OVID Ovid Therapeutics	2.7616 of 5 stars	$2.93 +5.0%	$4.63 +57.8%	+879.0%	$367.93M	$7.25M	N/A	60	Positive News Earnings Report Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ALDX) was last updated on 5/14/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Aldeyra Therapeutics (ALDX) Competitors

ALDX vs. PBYI, XFOR, AKBA, OVID, and IRD

How does Aldeyra Therapeutics compare to Puma Biotechnology?

Summary

How does Aldeyra Therapeutics compare to X4 Pharmaceuticals?

Summary

How does Aldeyra Therapeutics compare to Akebia Therapeutics?

Summary

How does Aldeyra Therapeutics compare to Ovid Therapeutics?

Summary

How does Aldeyra Therapeutics compare to Opus Genetics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALDX vs. The Competition

Aldeyra Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Aldeyra Therapeutics (ALDX) Competitors

ALDX vs. PBYI, XFOR, AKBA, OVID, and IRD

How does Aldeyra Therapeutics compare to Puma Biotechnology?

Do analysts recommend PBYI or ALDX?

Does the media prefer PBYI or ALDX?

Which has better earnings & valuation, PBYI or ALDX?

Which has more risk and volatility, PBYI or ALDX?

Is PBYI or ALDX more profitable?

Do insiders and institutionals have more ownership in PBYI or ALDX?

Summary

How does Aldeyra Therapeutics compare to X4 Pharmaceuticals?

Do analysts rate ALDX or XFOR?

Does the media favor ALDX or XFOR?

Which has stronger earnings & valuation, ALDX or XFOR?

Which has more volatility and risk, ALDX or XFOR?

Is ALDX or XFOR more profitable?

Do institutionals and insiders hold more shares of ALDX or XFOR?

Summary

How does Aldeyra Therapeutics compare to Akebia Therapeutics?

Is ALDX or AKBA more profitable?

Does the media refer more to ALDX or AKBA?

Do insiders & institutionals hold more shares of ALDX or AKBA?

Do analysts rate ALDX or AKBA?

Which has more volatility & risk, ALDX or AKBA?

Which has higher valuation and earnings, ALDX or AKBA?

Summary

How does Aldeyra Therapeutics compare to Ovid Therapeutics?

Is ALDX or OVID more profitable?

Does the media refer more to ALDX or OVID?

Which has stronger valuation & earnings, ALDX or OVID?

Do analysts rate ALDX or OVID?

Which has more risk & volatility, ALDX or OVID?

Do institutionals & insiders hold more shares of ALDX or OVID?

Summary

How does Aldeyra Therapeutics compare to Opus Genetics?

Does the media favor IRD or ALDX?

Is IRD or ALDX more profitable?

Do institutionals and insiders hold more shares of IRD or ALDX?

Which has better earnings & valuation, IRD or ALDX?

Which has more volatility and risk, IRD or ALDX?

Do analysts prefer IRD or ALDX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALDX vs. The Competition

Aldeyra Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools